Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Ixaltis gets funds to repurpose drug

by Ann M. Thayer
June 13, 2016 | A version of this story appeared in Volume 94, Issue 24

Ixaltis, a start-up company focused on urogenital disorders, has raised $9 million in its first funding round. The French firm’s pipeline consists of three compounds licensed from Sanofi. The most advanced is litoxetine, a serotonin reuptake inhibitor and 5-HT3 receptor antagonist that Sanofi had studied as an antidepressant. Ixaltis will soon begin testing the compound in a Phase II trial for treating urinary incontinence. The company also received a $3.2 million loan under an academic-industrial research project dedicated to urogenital diseases.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.